Corona Remedies (NSE:CORONA) ROCE %: 26.60% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
18 GF Score
Price ₹2,098.80
! 3 Warning Signs
View Full Analysis

What is Corona Remedies ROCE %?

Corona Remedies NSE:CORONA +0.37% 18 ROCE % is 26.60% as of Mar. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Corona Remedies's annualized ROCE % for the quarter that ended in Mar. 2026 was 26.60%.

Corona Remedies  (NSE:CORONA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Corona Remedies ROCE % Related Terms

Corona Remedies ROCE % Historical Data

* Premium members only.

The historical data trend for Corona Remedies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies ROCE % Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
ROCE %
24.75 24.43 31.86 31.94

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial 40.02 26.55 36.13 33.24 26.60
NSE:CORONA
18GF Score
Corona Remedies Ltd NSE:CORONA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies ROCE % Calculation

Corona Remedies's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=2449.9/( ( (9298.6 - 2395.9) + (12051.4 - 3611.7) )/ 2 )
=2449.9/( (6902.7+8439.7)/ 2 )
=2449.9/7671.2
=31.94 %

Corona Remedies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2244.8/( ( (0 - 0) + (12051.4 - 3611.7) )/ 1 )
=2244.8/( ( 0 + 8439.7 )/ 1 )
=2244.8/8439.7
=26.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.60% mean?
Corona Remedies (NSE:CORONA) has a ROCE % of 26.60% as of Mar. 2026.
Is Corona Remedies' ROCE % too high?
Corona Remedies' current ROCE % is 26.60%. The Drug Manufacturers industry median ROCE % is 7.03. Corona Remedies' value of 26.60% is 278.4% above this industry median. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' ROCE % compare to LLY and JNJ?
Corona Remedies' ROCE % of 26.60% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Corona Remedies' value of 26.60% is 278.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current ROCE % of 26.60% is 278.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current ROCE % is 26.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current ROCE % of 26.60%. The current ROCE % is 26.60% and 278.4% above the Drug Manufacturers industry median of 7.03. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current ROCE % is 26.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score

Get the complete analysis for NSE:CORONA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,098.80
Price